Navigation Links
Pieris Progresses Proprietary Asthma Program: Validation of,Pulmonary Delivery of Anticalin-Based Protein Product Candidate

FREISING-WEIHENSTEPHAN, Germany, July 10, 2007 /PRNewswire/ -- Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, today announced significant progress in validating novel, effective products for the potential treatment of asthma. In studies of its proprietary PRS-060 Anticalin(R) candidate, the Company reports that the protein can be effectively delivered to its target of action via the lungs.

PRS-060 has been selected by Pieris as being specific for a target implicated in a mechanism underlying asthma and other atopic diseases. The mode of action of the Anticalin(R) candidate is via modulation of the site of binding for multiple ligands.

"This important milestone demonstrates the exciting potential of Anticalin(R)-based products for the treatment of respiratory disease," said Dr Andreas Hohlbaum, Director of Science and Preclinical Development of Pieris. "In a simple preclinical biodistribution study quantitating PRS-060 Anticalin(R) delivered via a microspray device, we have already observed about 10-fold higher PRS-060 uptake than that typically obtained with monoclonal antibodies. Our findings have demonstrated the potential to deliver Anticalins(R) through alternative routes to injection and thereby exploit their intrinsic robustness and stability."

"This study confirms the ability of PRS-060 to be formulated in a way ideally suited to its application in asthma, namely in an inhaled preparation for home use," noted Evert Kueppers, Pieris Chief Executive Officer. "These findings continue to support the view that our Anticalin(R) platform, including its recent validation for dual targeting purposes, has enormous potential for application to human diseases that are currently inadequately treated."

The data will be presented for the first time on August 9th 2007 at IBC's Drug Discovery Technology Conference in Bost
'"/>




Page: 1 2

Related medicine technology :

1. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
2. Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific Anticalin in Preclinical Studies
3. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
4. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
5. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
6. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
7. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
8. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
9. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
10. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
11. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:10/2/2014)... Oct. 2, 2014  Perrigo Company plc (NYSE: ... laws of Ireland (the " Company ... (the "Exchange Offer") up to $500,000,000 of its new 1.30% ... $600,000,000 of its new 2.30% Senior Notes due 2018 (the ... Senior Notes due 2023 (the " 2023 Exchange Notes ") ...
(Date:10/2/2014)...   Softworld, Inc. announced today the launch of ... on the specific needs of pharmaceutical, biotech, and medical ... been highly successful in the clinical domain, the team ... the quality, regulatory, and validation space. ... the current Biometric team and the newly created Life ...
(Date:10/2/2014)... , Oct. 2, 2014  Isis Pharmaceuticals, ... following webcast:What: , Webcast and conference call to ... 2 clinical studies of ISIS-SMN Rx in ... which will be presented on the morning (CEST) ... World Muscle Society in Berlin, GermanyWhen:Friday, October 10 ...
Breaking Medicine Technology:Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 4Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress 2
... - Data From Phase 3 Study Presented at ... Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: WYE ... clinical trial that show patients with relapsed,and/or refractory ... treated with the mTOR (mammalian target of rapamycin) ...
... Show 100-Fold More Radiation Delivered to Tumor as Compared ... to Other Organs-, -All Patients ... ... TUSTIN, Calif., May 31 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported that ...
Cached Medicine Technology:New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 2New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 3New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 4New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 5New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 6Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 2Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 3Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 4Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 5
(Date:10/2/2014)... (HealthDay News) -- Scientists have pinpointed a molecule that ... colds. The researchers say this finding could offer ... treat these attacks. Most asthma attacks (80 percent ... the airways, according to the British researchers. Most of ... the common cold. The researchers found that a ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 (HealthDay ... reduced by breast-feeding. Nor will delaying the introduction of a ... help prevent celiac disease. Those are the conclusions ... New England Journal of Medicine . The new ... celiac disease if mothers breast-feed their babies and introduce gluten ...
(Date:10/2/2014)... discovery by scientists at The University of Nottingham could ... of painkiller. , A drug resulting from the research, ... would offer new hope to sufferers of chronic pain ... effective painkillers are currently available. , The work, led ... Life Sciences, in collaboration with David Bates, Professor of ...
(Date:10/1/2014)... Journal of the American Medical Association shows ... or severe chronic knee pain, acupuncture did not provide ... randomly assigned 282 patients (50 years or older) with ... pretend laser treatment. , Treatments were delivered for ... and sham (inactive) laser acupuncture. , Researcher Professor Kim ...
(Date:10/1/2014)... 1, 2014) Despite a policy focus on ... disabilities, this vulnerable population continues to have significant ... The Journal of the American Dental Association , ... Tufts University School of Dental Medicine report on ... at-home oral care provided by caregivers to adults ...
Breaking Medicine News(10 mins):Health News:New Clues to How Colds Can Spur Asthma Attacks 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Medical discovery first step on path to new painkillers 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3
... ask their physician will you be delivering my baby" ... to determine whether obstetric outcomes differed between women whose ... attended by an on-call obstetrician who did not provide ... live single term births between 1991 and 2001 at ...
... Aug. 21 issue of the Journal of the American ... found that people with a larger waist-to-hip ratio may ... evaluates the association between different measures of obesity and ... people who develop fat around the middle have more ...
... Spirometry testing is a widely accepted and encouraged diagnostic ... research shows that it is not used nearly enough. ... the peer-reviewed journal of the American College of Chest ... with a COPD diagnosis ever received spirometry testing. ...
... to prevent cluster headaches can cause heart problems, according ... issue of Neurology, the medical journal of the American ... cluster headaches should be closely monitored with frequent electrocardiograms ... headache is a rare, severe form of headache that ...
... individually or in combination, do not appear to reduce ... at high risk for heart disease, according to a ... Internal Medicine, one of the JAMA/Archives journals. , Oxidative ... to the development of cardiovascular disease, according to background ...
... and may produce beneficial changes in the brains and ... an article posted online today that will appear in ... one of the JAMA/Archives journals. , In patients with ... sheaths that protect nerve cells in the brain and ...
Cached Medicine News:Health News:Waist-to-hip ratio may better predict cardiovascular risk than body mass index 2Health News:Study says COPD testing is not measuring up 2Health News:Drug for cluster headaches may cause heart problems 2Health News:Antioxidants show no clear benefit against cardiovascular events, death in high-risk women 2Health News:DNA vaccine against multiple sclerosis appears safe, potentially beneficial 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: